Abstract
Abstract: :
Purpose: To evaluate the safety, efficacy, and predictability of VISX Custom Vue PRK for the treatment of myopia and compound myopic astigmatism. Methods: 30 eyes of 18 patients (mean age 37.3 ± 7.7 years) underwent uncomplicated Custom Vue wavefront–guided PRK using the VISX S4 Excimer Laser System for the treatment of myopia and compound myopic astigmatism. The mean preoperative spherical equivalent refraction was –4.20 ± 1.96 diopters (range –7.25 to –0.75 diopters). Results: All eyes were successfully imaged on the VISX WavePrint aberrometer preoperatively and underwent uneventful wavefront–guided Custom Vue PRK. All 30 eyes were re–epithelialized by day 6. There were no complications in the early post–operative period. Of the 30 eyes, 26 have had at least 2 week follow up. Using the data for follow up between the period of 2 weeks to one month, the average mean spherical equivalent refraction was –0.38 ± 0.57 diopters (range –1.25 to +1.00 diopters) with 100% of the eyes within 1 diopter of the attempted correction. 77% of the eyes were within 0.5 diopters of the attempted correction. 100% of the eyes achieved an uncorrected visual acuity of 20/40 or better, 77% achieved an UCVA of 20/25 or better, 62% achieved an UCVA of 20/20 or better, and 31% achieved an UCVA of 20/16 or better. Conclusions: Early visual results show that VISX Custom Vue PRK is safe and effective for the treatment of myopia and compound myopic astigmatism. Further results to be presented include predictability, vector analysis and pre and post–op higher order aberration analysis.
Keywords: refractive surgery: PRK